H., Kim, J., & Jang, Y
Other AMPs could also potentially be investigated, for instance LL-37 due to its anti-biofilm and antimicrobial properties (Ridyard and Overhage, 2021), histatins for their high biocompatibility and antifungal capabilities (Khurshid et al., 2017), ApoE (Yamazaki et al., 2016), enteric AMPs (Sivieri et al., 2017) or antimicrobial neuropeptides (El Karim et al., 2008)
Since the first GLP-1 received FDA approval for chronic weight management in 2014 (liraglutide, sold under the brand name Saxenda), 4 demand for these drugs has increased exponentially
Orforglipron: The First Approved Oral, Non-Peptide GLP-1R Agonist for Obesity orforglipron oral non-peptide GLP-1R agonist FDA approved for obesity / NDA planned for type 2 diabetes from LLC-PK1 cell HTS + opt N
Tell your doctor if you have ever had: Pancreas problems Kidney disease A severe stomach problem, such as problems with digesting food or slowed emptying of your stomach (gastroparesis) Are planning surgery or another procedure that uses anesthesia or deep sedation Diabetic retinopathy (a diabetes complication that affects the eyes) Gallbladder disease Pregnancy and fertility Tell your healthcare providers if you are pregnant or plan to become pregnant, as Zepbound may harm your unborn baby
